Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma

R. Vaclavikova, J. Klajic, V. Brynychova, K. Elsnerova, GIG. Alnaes, J. Tost, VN. Kristensen, L. Rob, R. Kodet, P. Skapa, M. Mrhalova, P. Soucek,

. 2019 ; 42 (2) : 763-774. [pub] 20190605

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006279

Grantová podpora
NV17-28470A MZ0 CEP - Centrální evidence projektů

Multidrug resistance to anticancer drugs, which is often associated with enhanced expression of the ATP‑binding cassette (ABC) transporter P‑glycoprotein (encoded by the ABCB1 gene) may limit the effects of cancer therapy. Epigenetic regulation of ABCB1 expression may thus have a clinical impact. A detailed assessment of ABCB1 promoter methylation is of importance for predicting therapy outcome and prognosis. Thus, validated methods for the analysis of ABCB1 promoter methylation are urgently required. In the present study, high‑resolution melting (HRM) analysis of the CpG island regions covering the distal promoter of the ABCB1 gene was developed and compared with pyrosequencing. In addition, the clinical effects of the methylation status of the ABCB1 promoter were analyzed in patients with breast and ovarian carcinoma prior and subsequent to chemotherapy treatment. HRM analysis of ABCB1 methylation correlated with the results of pyrosequencing (P=0.001) demonstrating its analytical validity and utility. Hypermethylation of the analyzed ABCB1 promoter region was significantly correlated with low levels of the ABCB1 transcript in tumors from a subset of patients with breast and ovarian carcinoma prior to chemotherapy but not following treatment. Finally, high ABCB1 transcript levels were observed in tumors of patients with short progression‑free survival prior to chemotherapy. Our data suggest the existence of functional epigenetic changes in the ABCB1 gene with prognostic value in tumor tissues of patients with breast and ovarian carcinoma. The clinical importance of such changes should be further evaluated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006279
003      
CZ-PrNML
005      
20200526134306.0
007      
ta
008      
200511s2019 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2019.7186 $2 doi
035    __
$a (PubMed)31173253
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Vaclavikova, Radka $u Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic.
245    10
$a Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma / $c R. Vaclavikova, J. Klajic, V. Brynychova, K. Elsnerova, GIG. Alnaes, J. Tost, VN. Kristensen, L. Rob, R. Kodet, P. Skapa, M. Mrhalova, P. Soucek,
520    9_
$a Multidrug resistance to anticancer drugs, which is often associated with enhanced expression of the ATP‑binding cassette (ABC) transporter P‑glycoprotein (encoded by the ABCB1 gene) may limit the effects of cancer therapy. Epigenetic regulation of ABCB1 expression may thus have a clinical impact. A detailed assessment of ABCB1 promoter methylation is of importance for predicting therapy outcome and prognosis. Thus, validated methods for the analysis of ABCB1 promoter methylation are urgently required. In the present study, high‑resolution melting (HRM) analysis of the CpG island regions covering the distal promoter of the ABCB1 gene was developed and compared with pyrosequencing. In addition, the clinical effects of the methylation status of the ABCB1 promoter were analyzed in patients with breast and ovarian carcinoma prior and subsequent to chemotherapy treatment. HRM analysis of ABCB1 methylation correlated with the results of pyrosequencing (P=0.001) demonstrating its analytical validity and utility. Hypermethylation of the analyzed ABCB1 promoter region was significantly correlated with low levels of the ABCB1 transcript in tumors from a subset of patients with breast and ovarian carcinoma prior to chemotherapy but not following treatment. Finally, high ABCB1 transcript levels were observed in tumors of patients with short progression‑free survival prior to chemotherapy. Our data suggest the existence of functional epigenetic changes in the ABCB1 gene with prognostic value in tumor tissues of patients with breast and ovarian carcinoma. The clinical importance of such changes should be further evaluated.
650    _2
$a P-glykoproteiny $x genetika $7 D018435
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a nádory prsu $x farmakoterapie $x genetika $x patologie $7 D001943
650    _2
$a duktální karcinom prsu $x farmakoterapie $x genetika $x patologie $7 D018270
650    _2
$a serózní cystadenokarcinom $x farmakoterapie $x genetika $x patologie $7 D018284
650    12
$a metylace DNA $7 D019175
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a denaturace nukleových kyselin $7 D009691
650    _2
$a nádory vaječníků $x farmakoterapie $x genetika $x patologie $7 D010051
650    _2
$a polymerázová řetězová reakce $x metody $7 D016133
650    _2
$a prognóza $7 D011379
650    12
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
700    1_
$a Klajic, Jovana $u Division of Medicine, Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway.
700    1_
$a Brynychova, Veronika $u Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic.
700    1_
$a Elsnerova, Katerina $u Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic.
700    1_
$a Alnaes, Grethe I G $u Department of Genetics, Institute for Cancer Research, Rikshospitalet‑Radiumhospital Medical Center, 0372 Oslo, Norway.
700    1_
$a Tost, Jörg $u Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA‑Institut de Génomique, 91057 Evry, France.
700    1_
$a Kristensen, Vessela N $u Division of Medicine, Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway.
700    1_
$a Rob, Lukas $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and Vinohrady University Hospital, Charles University, 10034 Prague.
700    1_
$a Kodet, Roman $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University in Prague, 15006 Prague, Czech Republic.
700    1_
$a Skapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University in Prague, 15006 Prague, Czech Republic.
700    1_
$a Mrhalova, Marcela $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University in Prague, 15006 Prague, Czech Republic.
700    1_
$a Soucek, Pavel $u Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic.
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 42, č. 2 (2019), s. 763-774
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31173253 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526134302 $b ABA008
999    __
$a ok $b bmc $g 1525137 $s 1096335
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 42 $c 2 $d 763-774 $e 20190605 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
GRA    __
$a NV17-28470A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace